J Obes Metab Syndr.  2019 Mar;28(1):18-29. 10.7570/jomes.2019.28.1.18.

The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

• Jung CH
• Mok JO

• KMID: 2452623
• DOI: http://doi.org/10.7570/jomes.2019.28.1.18

Abstract

The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their effects on NAFLD have received substantial interest. Herein, we review the currently available human studies regarding the effects of SGLT2 inhibitors and GLP-1RAs on NAFLD/non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus, and we describe the possible mechanisms explaining the positive effects of these agents on NAFLD.

Keyword

Sodium-glucose cotransporter 2 inhibitor; Glucagon-like peptide-1 receptor agonist; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus

MeSH Terms

Diabetes Mellitus, Type 2
Drug Therapy
Fatty Liver
Glucagon-Like Peptide 1*
Glucagon-Like Peptide-1 Receptor*
Humans
Hypoglycemic Agents*
Non-alcoholic Fatty Liver Disease*
Weight Loss
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents